Literature DB >> 18787170

FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.

Jian-Hua Mao1, Il-Jin Kim, Di Wu, Joan Climent, Hio Chung Kang, Reyno DelRosario, Allan Balmain.   

Abstract

The enzyme mTOR (mammalian target of rapamycin) is a major target for therapeutic intervention to treat many human diseases, including cancer, but very little is known about the processes that control levels of mTOR protein. Here, we show that mTOR is targeted for ubiquitination and consequent degradation by binding to the tumor suppressor protein FBXW7. Human breast cancer cell lines and primary tumors showed a reciprocal relation between loss of FBXW7 and deletion or mutation of PTEN (phosphatase and tensin homolog), which also activates mTOR. Tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, which suggests that loss of FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18787170      PMCID: PMC2849753          DOI: 10.1126/science.1162981

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  18 in total

1.  Deletion of chromosome 11q predicts response to anthracycline-based chemotherapy in early breast cancer.

Authors:  Joan Climent; Peter Dimitrow; Jane Fridlyand; Jose Palacios; Reiner Siebert; Donna G Albertson; Joe W Gray; Daniel Pinkel; Ana Lluch; Jose A Martinez-Climent
Journal:  Cancer Res       Date:  2007-01-15       Impact factor: 12.701

Review 2.  Small molecule antagonists of the MDM2 oncoprotein as anticancer agents.

Authors:  John K Buolamwini; James Addo; Shantaram Kamath; Shivaputra Patil; Darius Mason; Marian Ores
Journal:  Curr Cancer Drug Targets       Date:  2005-02       Impact factor: 3.428

3.  CDC4 mutations occur in a subset of colorectal cancers but are not predicted to cause loss of function and are not associated with chromosomal instability.

Authors:  Zoe Kemp; Andrew Rowan; William Chambers; Noel Wortham; Sarah Halford; Oliver Sieber; Neil Mortensen; Axel von Herbay; Thomas Gunther; Mohammad Ilyas; Ian Tomlinson
Journal:  Cancer Res       Date:  2005-12-15       Impact factor: 12.701

4.  Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene.

Authors:  Jian-Hua Mao; Jesus Perez-Losada; Di Wu; Reyno Delrosario; Ryosuke Tsunematsu; Keiichi I Nakayama; Ken Brown; Sheila Bryson; Allan Balmain
Journal:  Nature       Date:  2004-12-09       Impact factor: 49.962

5.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.

Authors:  Richard M Neve; Koei Chin; Jane Fridlyand; Jennifer Yeh; Frederick L Baehner; Tea Fevr; Laura Clark; Nora Bayani; Jean-Philippe Coppe; Frances Tong; Terry Speed; Paul T Spellman; Sandy DeVries; Anna Lapuk; Nick J Wang; Wen-Lin Kuo; Jackie L Stilwell; Daniel Pinkel; Donna G Albertson; Frederic M Waldman; Frank McCormick; Robert B Dickson; Michael D Johnson; Marc Lippman; Stephen Ethier; Adi Gazdar; Joe W Gray
Journal:  Cancer Cell       Date:  2006-12       Impact factor: 31.743

6.  Genomic and transcriptional aberrations linked to breast cancer pathophysiologies.

Authors:  Koei Chin; Sandy DeVries; Jane Fridlyand; Paul T Spellman; Ritu Roydasgupta; Wen-Lin Kuo; Anna Lapuk; Richard M Neve; Zuwei Qian; Tom Ryder; Fanqing Chen; Heidi Feiler; Taku Tokuyasu; Chris Kingsley; Shanaz Dairkee; Zhenhang Meng; Karen Chew; Daniel Pinkel; Ajay Jain; Britt Marie Ljung; Laura Esserman; Donna G Albertson; Frederic M Waldman; Joe W Gray
Journal:  Cancer Cell       Date:  2006-12       Impact factor: 31.743

7.  A nucleolar isoform of the Fbw7 ubiquitin ligase regulates c-Myc and cell size.

Authors:  Markus Welcker; Amir Orian; Jonathan E Grim; Jonathan A Grim; Robert N Eisenman; Bruce E Clurman
Journal:  Curr Biol       Date:  2004-10-26       Impact factor: 10.834

8.  Pten is essential for embryonic development and tumour suppression.

Authors:  A Di Cristofano; B Pesce; C Cordon-Cardo; P P Pandolfi
Journal:  Nat Genet       Date:  1998-08       Impact factor: 38.330

9.  FBXW7/hCDC4 is a general tumor suppressor in human cancer.

Authors:  Shahab Akhoondi; Dahui Sun; Natalie von der Lehr; Sophia Apostolidou; Kathleen Klotz; Alena Maljukova; Diana Cepeda; Heidi Fiegl; Dimitra Dafou; Dimitra Dofou; Christian Marth; Elisabeth Mueller-Holzner; Martin Corcoran; Markus Dagnell; Sepideh Zabihi Nejad; Babak Noori Nayer; Mohammad Reza Zali; Johan Hansson; Susanne Egyhazi; Fredrik Petersson; Per Sangfelt; Hans Nordgren; Dan Grander; Steven I Reed; Martin Widschwendter; Olle Sangfelt; Charles Spruck
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

10.  Breast tumor copy number aberration phenotypes and genomic instability.

Authors:  Jane Fridlyand; Antoine M Snijders; Bauke Ylstra; Hua Li; Adam Olshen; Richard Segraves; Shanaz Dairkee; Taku Tokuyasu; Britt Marie Ljung; Ajay N Jain; Jane McLennan; John Ziegler; Koei Chin; Sandy Devries; Heidi Feiler; Joe W Gray; Frederic Waldman; Daniel Pinkel; Donna G Albertson
Journal:  BMC Cancer       Date:  2006-04-18       Impact factor: 4.430

View more
  209 in total

1.  Negative regulation of HIF-1α by an FBW7-mediated degradation pathway during hypoxia.

Authors:  Jessica M Cassavaugh; Sarah A Hale; Theresa L Wellman; Alan K Howe; Cheung Wong; Karen M Lounsbury
Journal:  J Cell Biochem       Date:  2011-12       Impact factor: 4.429

2.  Monitoring the outside: cell wall-sensing mechanisms.

Authors:  Christoph Ringli
Journal:  Plant Physiol       Date:  2010-05-27       Impact factor: 8.340

3.  C/EBPδ: friend or foe? a novel role for C/EBPδ in metastasis.

Authors:  Facundo G Pelorosso; Allan Balmain
Journal:  EMBO J       Date:  2010-12-15       Impact factor: 11.598

4.  The tumour suppressor C/EBPδ inhibits FBXW7 expression and promotes mammary tumour metastasis.

Authors:  Kuppusamy Balamurugan; Ju-Ming Wang; Hsin-Hwa Tsai; Shikha Sharan; Miriam Anver; Robert Leighty; Esta Sterneck
Journal:  EMBO J       Date:  2010-11-12       Impact factor: 11.598

Review 5.  Dysregulation of ubiquitin ligases in cancer.

Authors:  Jianfei Qi; Ze'ev A Ronai
Journal:  Drug Resist Updat       Date:  2015-09-28       Impact factor: 18.500

6.  miR-223/FBW7 axis regulates doxorubicin sensitivity through epithelial mesenchymal transition in non-small cell lung cancer.

Authors:  Renyuan Li; Shengjun Wu; Xin Chen; Hongfei Xu; Peng Teng; Weidong Li
Journal:  Am J Transl Res       Date:  2016-06-15       Impact factor: 4.060

7.  Rictor regulates FBXW7-dependent c-Myc and cyclin E degradation in colorectal cancer cells.

Authors:  Zheng Guo; Yuning Zhou; B Mark Evers; Qingding Wang
Journal:  Biochem Biophys Res Commun       Date:  2012-01-20       Impact factor: 3.575

Review 8.  Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.

Authors:  Jonathan D Black; Diana P English; Dana M Roque; Alessandro D Santin
Journal:  Womens Health (Lond)       Date:  2014-01

Review 9.  PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects.

Authors:  Vera P Krymskaya; Elena A Goncharova
Journal:  Cell Cycle       Date:  2009-02-06       Impact factor: 4.534

Review 10.  Targeting the ubiquitin pathway for cancer treatment.

Authors:  Jia Liu; Shavali Shaik; Xiangpeng Dai; Qiong Wu; Xiuxia Zhou; Zhiwei Wang; Wenyi Wei
Journal:  Biochim Biophys Acta       Date:  2014-12-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.